Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7876 - 7900 of 8033 in total
Investigational
Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.[A257048,A257053]
Investigational
ATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon. Releasing the drug directly into the colon reduces the potential for significant side effects often experienced with steroid drugs. Colal-Pred is being studied for use in ulcerative colitis.
Investigational
Cenisertib is an aurora kinase inhibitor.
Investigational
NV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.
Investigational
TRC093 is a recombinant humanized IgG1k monoclonal antibody.
Investigational
Methopterin is thought to have effects on osteoclasts and to inhibit inflammatory bone destruction.
Investigational
RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.
Investigational
Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
Investigational
Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
Investigational
Investigational
Investigational
Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP.[L27171,L27176] In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.
Investigational
Opaganib, also known as ABC294640, is a selective sphingosine kinase-2 (SK2) (https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered. This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19.
Investigational
Investigational
Investigational
Investigational
A MET receptor tyrosine kinase inhibitor.
Investigational
Investigational
Investigational
TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
Investigational
Investigational
Human amniotic fluid is the liquid surrounding the human embryo and fetus. Physically, the fluid provides protection through cushioning. Chemically, the fluid provides protection through its inherent antibacterial properties. The fluid contains carbohydrates, proteins, lipids, electrolytes, urea, immunoglobulins, growth factors, and vitamins.[L16373,L16378]
Investigational
Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
Investigational
Investigational
Displaying drugs 7876 - 7900 of 8033 in total